Sidoti Csr Issues Positive Estimate for USNA Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Investment analysts at Sidoti Csr lifted their Q3 2025 earnings per share estimates for shares of USANA Health Sciences in a research note issued to investors on Wednesday, February 26th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will earn $0.72 per share for the quarter, up from their prior estimate of $0.70. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q3 2025 earnings at $0.72 EPS, Q3 2026 earnings at $0.98 EPS and Q3 2026 earnings at $0.98 EPS.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%.

Several other equities research analysts also recently issued reports on USNA. Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. DA Davidson dropped their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th.

USANA Health Sciences Stock Down 14.0 %

NYSE:USNA opened at $28.57 on Friday. The company has a fifty day moving average of $33.50 and a 200-day moving average of $36.56. USANA Health Sciences has a twelve month low of $27.71 and a twelve month high of $50.32. The firm has a market capitalization of $544.54 million, a P/E ratio of 10.10, a P/E/G ratio of 0.93 and a beta of 0.87.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning purchased a new position in shares of USANA Health Sciences in the 3rd quarter worth about $394,000. Allspring Global Investments Holdings LLC increased its stake in shares of USANA Health Sciences by 14,068.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock worth $1,472,000 after purchasing an additional 38,547 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of USANA Health Sciences by 44.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 8,859 shares of the company’s stock worth $336,000 after purchasing an additional 2,713 shares during the period. KBC Group NV grew its holdings in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after purchasing an additional 519 shares during the period. Finally, Royce & Associates LP grew its stake in shares of USANA Health Sciences by 22.2% during the 3rd quarter. Royce & Associates LP now owns 33,143 shares of the company’s stock worth $1,257,000 after acquiring an additional 6,031 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.